Dissecting the molecular antifibrotic effect of the TGF-Beta(I) receptor kinase inhibitor galunisertib in precision-cut liver slices

1st International Conference on Fatty Liver (ICFL). Seville, June 1-3, 2017: Abstracts

Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis

Background and Purpose Liver fibrosis is a major cause of liver-related mortality and, so far, no effective antifibrotic drug is available. Galunisertib, a TGF-β receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis. Here, we evaluated the potency of galunisertib in a human ex vivo model of liver fibrosis. Experimental Approach Antifibrotic potency and associated mechanisms were studied ex vivo, using both healthy and cirrhotic human precision-cut liver slices. Fibrosis-related parameters, both transcriptional and translational level, were assessed after treatment with galunisertib. Key Results Galunisertib showed a prominent antifibrotic potency. Ph…